We investigated whether blood N-
glycan changes can be used as a diagnostic
biomarker for
Alzheimer disease (AD). We used
DNA sequencer-assisted, fluorophore-assisted
carbohydrate electrophoresis (DSA-FACE) technology to assay N-
glycans in sera from 79 autopsy-confirmed
dementia patients and 149 healthy controls. One N-
glycan (NA2F) was substantially decreased in AD patients but not in controls. Use of NA2F for discriminating AD between
dementia patients and healthy controls showed a diagnostic accuracy of 85.7% +/- 2.8% with 92% specificity and 70% sensitivity. The decrease in the level of NA2F in AD patients compared to non-AD patients was more pronounced in females (p < 0.0001) than in males (p < 0.014). Use of NA2F to differentiate female AD from female non-AD patients reached a diagnostic accuracy of 90.7% +/- 4.8 %. Pearson correlation analysis showed that in female
dementia patients, serum NA2F levels were significantly correlated with the cerebrospinal fluid (CSF)
beta-amyloid peptide of 42
amino acids (Abeta(1-42)) and tau phosphorylated at
threonine 181 (P-tau(181P)) levels, whereas in male
dementia patients serum NA2F levels were significantly correlated only with CSF total
tau protein (T-tau) level. Thus, we suggest that the serum N-
glycan marker might be suitable for longitudinal and follow-up studies.